tag:blogger.com,1999:blog-5424255638293718915.post8990366354257634799..comments2024-03-18T01:10:51.745-05:00Comments on neuropathology blog: Immunohistochemical surrogate for IDH1 mutationBrian E. Moore, MD, MEdhttp://www.blogger.com/profile/17503916201692804693noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-5424255638293718915.post-208249395947693522016-03-02T15:11:27.653-06:002016-03-02T15:11:27.653-06:00Not being a white-collar neuropathologist, I would...Not being a white-collar neuropathologist, I wouldn't know for sure. But, I would think that they might handle IDH1 IHC negative tumors by assuming they are indeed not mutated EXCEPT in cases where ATRX IHC nuclear staining is lost, in which case they would reflex to a molecular test to find either the IDH1 mutation missed by IDH1 IHC or non-canonical IDH mutations.<br /><br />Thanks for commenting, Agent 86!Brian E. Moore, MD, MEdhttps://www.blogger.com/profile/17503916201692804693noreply@blogger.comtag:blogger.com,1999:blog-5424255638293718915.post-1875035513943367182016-02-17T18:04:59.858-06:002016-02-17T18:04:59.858-06:00Thanks, Brian.
I'm not great with math, but 9...Thanks, Brian.<br /><br />I'm not great with math, but 90% concordance with the IDH1 base substitution recognized by the commercially available antibody (which occurs 90% of the time) suggests that IDH1-R132H IHC may miss about 1 in 5 IDH-mutated gliomas. I'd like to know what your molecularly adept/white-collar neuropathologist readers are doing with IDH1-R132H IHC negative tumors (especially non-GBMs). <br /><br />It was also interesting to read that the commercial antibody may pick up a certain number of other IDH1 point mutations.<br /><br />A86Agent 86noreply@blogger.com